Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

NCT06663059 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle
DRUG: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle

Sponsor

Tang-Du Hospital